Surmodics, Inc. provides medical device and in vitro diagnostic technologies for the health care industry. Its company news has included clinical and regulatory disclosures for the Pounce™ Thrombectomy Platform, including PROWL Registry analyses of peripheral arterial thrombectomy in symptomatic lower-extremity limb ischemia.
Coverage has also included operating and financial results, material agreements, capital-structure updates, and the completed 2025 merger that converted Surmodics from a Nasdaq-listed public company into a wholly owned subsidiary. Product-related updates focus on FDA-cleared mechanical thrombectomy systems designed for non-surgical removal of emboli and thrombi in the peripheral arterial vasculature.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.